{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-141756","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.151545+00:00","generated_at":"2026-05-19T04:39:44.404458+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spyre reports positive Phase 1 data for SPY002 & SPY072; half-life ~75 days, Phase 2 trials initiated","bullets":["SPY002 and SPY072 well tolerated up to 1500 mg; no serious AEs, no TEAEs >Grade 2, no discontinuations.","SPY002 half-life ~75 days (≥3x first-gen anti-TL1As); supports quarterly or twice-yearly SC dosing.","Single 100 mg dose of either antibody suppressed free TL1A below LLOQ through 20 weeks.","SKYLINE-UC (UC) platform trial started May 2025; SKYWAY-RD basket (RA, PsA, axSpA) planned Q3 2025.","Expects 9 Phase 2 readouts by 2027; cash runway into H2 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-141756","json":"https://secwatch.observer/filing/0001193125-25-141756.json","markdown":"https://secwatch.observer/filing/0001193125-25-141756.md","text":"https://secwatch.observer/filing/0001193125-25-141756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312525141756/0001193125-25-141756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312525141756/d18728d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:39:44.404458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}